Scarica l'app Stockscreener
116.78
2.82%
3.20
Pre-mercato:
116.66
-0.12
-0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Gilead Sciences Inc Borsa (GILD) Ultime notizie
Triasima Portfolio Management inc. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Friedenthal Financial Purchases Shares of 9,152 Gilead Sciences, Inc. $GILD - MarketBeat
Valeo Financial Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
DAVENPORT & Co LLC Sells 16,332 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years - Benzinga
Gilead Sciences stock rises as Bernstein reiterates Outperform rating - Investing.com
KLP Kapitalforvaltning AS Purchases 20,100 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - Zacks Investment Research
Going Beyond – Ending the HIV epidemic by 2030 : From Belgium to the EU - Gilead Sciences
Gilead inks trio of Biktarvy patent settlements, waylaying US copycats until 2036 - Fierce Pharma
Gilead Sciences 2025: Slow and steady - PharmaLive
Gilead Sciences, Inc. $GILD Shares Bought by Merit Financial Group LLC - MarketBeat
Gilead Sciences Settles Patent Litigations With Generic Drugmakers For Best-Selling HIV Drug: Analyst Cheers Longer Runway - Stocktwits
Gilead Gets HIV Generic Drugs Barred From Market Until 2036 - Law360
Gilead Scores A 'Solid Win' For Its Biggest Moneymaker; Shares Jump - Investor's Business Daily
Gilead (GILD) Reaches Settlement in HIV Treatment Patent Lawsuit - GuruFocus
Gilead, Cipla Settlement Blocks Copies of Biktarvy HIV Drug - Bloomberg Law News
Gilead Reaches Settlement To Block Biktarvy Generics Until 2036Gilead Sciences (NASDAQ:GILD) - Benzinga
Gilead Shares Rise After Reaching Settlement on Biktarvy Patent Disputes - MSN
Gilead Sciences (GILD) Announces Settlement Agreements to Resolve Patent Litigations - GuruFocus
Gilead Sciences (GILD) Secures Patent Protection for Biktarvy Un - GuruFocus
Gilead (GILD) Resolves Patent Disputes Over Biktarvy - GuruFocus
Gilead Sciences Settles Patent Litigation on Biktarvy - TipRanks
Gilead stock rises after settling Biktarvy patent disputes By Investing.com - Investing.com Canada
Gilead stock rises after settling Biktarvy patent disputes - Investing.com
Needham reiterates Buy rating on Gilead stock, sees promise in inflammation pipeline - Investing.com
Gilead Sciences Inc announces settlement agreements with Lupin, Cipla and Laurus LabsSEC filing - MarketScreener
Gilead Sciences reaches settlement on Biktarvy patent litigation with generics - Investing.com
Gilead settles patent disputes over Biktarvy with generic drugmakers - StreetInsider
Gilead Sciences: Strategic Diversification and Promising Inflammation Pipeline Justify Buy Rating - TipRanks
Grimes & Company Inc. Has $17.44 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Valuation After Kymera Oncology Partnership and Revenue Growth Momentum - simplywall.st
AMF Tjanstepension AB Purchases 154,530 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Holdings Boosted by LGT Fund Management Co Ltd. - MarketBeat
111 Capital Sells 9,679 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Ascent Group LLC Grows Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Laps the Stock Market: Here's Why - sharewise.com
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Sells 9,506 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences: Strong Growth Potential Driven by Yeztugo Launch and Strategic Positioning - TipRanks
RBC Capital Maintains a Hold Rating on Gilead Sciences (GILD) - Insider Monkey
Gilead Foundation Commits Over $6.5M in New Grant Funding to Support STEM Education Pathways - Yahoo Finance
Truist Financial Corp Sells 7,052 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
How Gilead Sciences Inc. (Common Stock) (GIS0) stock responds to bond marketMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com
Will Gilead Sciences Inc. (Common Stock) (GIS0) stock recover faster than industry2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo
Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock. - Barron's
J. Safra Sarasin Holding AG Reduces Stake in Gilead Sciences, Inc. $GILD - MarketBeat
USA Financial Formulas Boosts Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead stock faces potential hit if Biktarvy is Trump’s price cut target - Investing.com
Potential Price Pressures for Gilead (GILD) Shares - GuruFocus
RBC on Gilead Sciences (GILD): 'Could Biktarvy Be The $137 Pill Trump Wants To Cut To $18' - StreetInsider
Marginal Zone Lymphoma Market Growth Projections 2024-2034: DelveInsight Analysis | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma - The Globe and Mail
Trilogy Capital Inc. Has $3.05 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Immatics Appoints Venkat Ramanan as Chief Financial Officer - GlobeNewswire Inc.
Using flow based indicators on Gilead Sciences Inc.2025 Sector Review & Short-Term High Return Strategies - newser.com
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - MSN
Insider Sell: Daniel O'Day Sells 10,000 Shares of Gilead Sciences Inc (GILD) - GuruFocus
How to integrate Gilead Sciences Inc. into portfolio analysis toolsEarnings Miss & Weekly High Conviction Trade Ideas - newser.com
What Do Analysts Think About Gilead Sciences (GILD)? - Insider Monkey
Gilead signs $34.5M deal for Hanmi/HHP’s I.V.-to-oral drug tech - BioWorld MedTech
Gilead Sciences Begins On New California Manufacturing Hub - Construction Equipment Guide
One Wealth Advisors LLC Has $1.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Earnings visualization tools for Gilead Sciences Inc.2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Capital Investment Advisors LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Raleigh Capital Management Inc. Sells 6,315 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
GC Wealth Management RIA LLC Boosts Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Avior Wealth Management LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Hong Kong's Health Hope Pharma enters into virology deal with Gilead Sciences - BioSpectrum Asia
0.61%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):